Professor Yuling Ma‌
Director of the Oxford University Chinese Medicine Research Centre, Principal Investigator at the University of Oxford, and Fellow of the
British Pharmacological Society. She is dedicated to researching the mechanisms of traditional Chinese medicine (TCM) formulas and promoting their global adoption.‌

• ‌Education‌:

  • B.Sc. in Biology, Peking University.
  • M.Sc. (1985) from the China Academy of Chinese Medical Sciences.
  • Ph.D. (1995) from the University of London, focusing on the pharmacological actions of herbal medicines.

• ‌Leadership‌:

  • Founded Oxford University’s first TCM research unit in 2014, later expanded into the Oxford University Chinese Medicine Research Centre in 2017.

• ‌Landmark Research‌:

  • Led mechanistic studies on the TCM formula Xin Su Ning Capsule, demonstrating its ability to ‌reversibly inhibit myocardial potassium/sodium channels‌, prolong action potential duration, and significantly reduce toxicity risks of antiarrhythmic drugs.
  • Findings secured a ‌U.S. patent (2021)‌ and were published in top-tier international journals.

• ‌Global Collaboration‌:

  • Partnered with Shaanxi M&H Pharmaceutical (2019) to establish a joint research centre for TCM formula innovation.
  • Advocated for TCM globalization at the China-ASEAN Education Cooperation Week (2023).

• ‌Academic Influence‌:

  • Delivered keynote speeches at global forums (e.g., 2024 World Congress of Chinese Medicine, 2023 China-ASEAN Forum), sharing interdisciplinary approaches bridging cell biology and TCM.

• ‌Recognition‌:

  • Research endorsed by global pharmacology leaders, including Professor Humphrey Rang, former Chair of the British Pharmacological Society.
  • Featured by Global SciPod for advancing integrative medicine.

Guided by the TCM philosophy of "Da Yi Jing Cheng" (Great Medicine Serves with Sincerity and Mastery), her work integrates modern science to propel evidence-based TCM development worldwide.